Panacea Biotech

Panacea Biotech rallied over 1.3% in the early morning trades to Rs.163.20 and continues to remain in the green. Volumes have shown a spike up of over 2.5 times. Its 52-week high is at Rs.178.30.

It took 10 years for the company’s R&D department to discover this new vaccination. Known as EasySix, it is a liquid hexavalent combination vaccine indicated for immunisation of newborn babies against common preventable diseases.

This is world's first fully liquid whole cell pertussis based vaccine and would work against diseases as diphtheria, tetanus, whooping cough, meningitis, hepatitis B and polio.

This new vaccination is expected to give a great boost to the company’s bottomline once the product is marketed well and gets accepted in the new born vaccination segment. Even now there does exists a one-for-all vaccination but it is imported and cost is very high, with many also not believing in the efficacy of this one-for-all vaccination. Thus a carefully drawn out campaign will be required to dispel all fears; only then will the 10 years of R&D start showing in the bottomline.